CyDex Pharmaceuticals Accuses Bexson Biomedical of Contract Breach Over Drug Formulations

CyDex Pharmaceuticals has initiated legal proceedings against Bexson Biomedical, alleging a breach of contract in Delaware Chancery Court. The core of CyDex’s claim centers on the accusation that Bexson improperly utilized a molecule designed by CyDex to create unauthorized non-ketamine formulations. Additionally, CyDex contends that Bexson subsequently filed for a patent on these formulations, an action that purportedly violates the terms of their agreement. For more details, please refer to the original article.